Oruka Therapeutics, Inc. Increase (Decrease) in Notes Receivable, Related Parties, Current
Oruka Therapeutics, Inc. (ORKA) reported Increase (Decrease) in Notes Receivable, Related Parties, Current of -$1.00 thousand for the 5-month period ending 2024-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent · last filed 2025-08-11
- 2024-06-30: Increase (Decrease) in Notes Receivable, Related Parties, Current 5 month -$1.00K.
- 2024-03-31: Increase (Decrease) in Notes Receivable, Related Parties, Current 2 month -$1.00K.
| Period end | Increase (Decrease) in Notes Receivable, Related Parties, Current 2 month | Increase (Decrease) in Notes Receivable, Related Parties, Current 5 month |
|---|---|---|
| 2024-06-30 | -$1.00K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | -$1.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |